Dubuque Bank & Trust Co. Has $11.48 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Dubuque Bank & Trust Co. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 7.3% during the third quarter, HoldingsChannel.com reports. The firm owned 70,275 shares of the company’s stock after selling 5,559 shares during the period. Johnson & Johnson makes up approximately 1.6% of Dubuque Bank & Trust Co.’s portfolio, making the stock its 12th biggest holding. Dubuque Bank & Trust Co.’s holdings in Johnson & Johnson were worth $11,480,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JNJ. RKL Wealth Management LLC raised its position in shares of Johnson & Johnson by 2.1% during the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after acquiring an additional 1,010 shares during the last quarter. Geller Advisors LLC raised its position in shares of Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares during the last quarter. Simon Quick Advisors LLC raised its position in shares of Johnson & Johnson by 296.9% during the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after acquiring an additional 6,537 shares during the last quarter. Lokken Investment Group LLC raised its position in shares of Johnson & Johnson by 1.6% during the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after acquiring an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP raised its position in shares of Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after acquiring an additional 525 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. Citigroup raised their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Sanford C. Bernstein lowered their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Wednesday. The stock has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business’s 50 day moving average is $175.98 and its 200 day moving average is $171.06.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.12. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.